A Stent for Every Stone? Prestenting Habits and Outcomes from a German Multicenter Prospective Study on the Benchmarks of Ureteroroscopic Stone Treatment (BUSTER)
Peter Werthemann(Vivantes Klinikum), Steffen Lebentrau(Medizinische Hochschule Brandenburg Theodor Fontane), Thomas Enzmann(Universitätsklinikum Brandenburg an der Havel), Martin Schostak(Aturo), Steffen Weikert(St. Hedwig-Krankenhaus)
Cited by 11
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
|International Journal of Molecular Medicine|2005|151
miRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome
|Journal of Molecular Diagnostics|2013|144